And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda calls for manicuring the Pharmalot campus, hanging with our shortest short person, indulging in still more ancient rituals and, otherwise, simply lounging about. And what about you? This is a fine time to sift through apple orchards and pumpkin patches. You could stock up on winter gear before prices rise still more. Perhaps you could double-check to ensure you are registered to vote. The U.S. is still a democracy, after all. Or you could make time to reach out to someone special and make them feel important. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
The drug-pricing law will still penalize pharmaceutical companies if they hike prices on medicines for patients who have private insurance, STAT says. The penalties may factor into decisions for pricing medicines as the new law begins to take effect. Some experts and employers have been concerned that the drug-pricing policy reforms that will save money in Medicare could incentivize drugmakers to try to charge more to patients with other forms of insurance coverage. “One thing that I think is important to know is the inflation rebate is determined on the overall price. So it’s including commercial [prices] in there,” explained Center for Medicare Director Meena Seshamani.
In the run-up to an extremely unusual hearing later this month, newly released documents underscore highly contrasting views taken by the U.S. Food and Drug Administration and a manufacturer toward a controversial drug for reducing premature births, which the agency wants withdrawn from the market, STAT writes. For the first time, the FDA explained in copious detail why agency officials believe the medication, which is called Makena, should be removed. The briefing documents, released in advance of the three-day session, also pushed back considerably against arguments made by Covis Pharma, the manufacturer, for continuing to make its drug available to American women.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect